The US Food and Drug Administration (FDA) has sharply increased unannounced inspections at pharmaceutical manufacturing facilities in India, making surprise visits a much bigger part of its overseas regulatory oversight. In fiscal year 2026, 87% of the agency’s inspections in India were unannounced, compared with 47% in fiscal 2025, according to figures disclosed by a senior FDA official in November.
The change signals a tougher inspection environment for Indian drugmakers supplying the US market, one of the industry’s most important export destinations. The FDA says the objective is to observe normal manufacturing conditions rather than operations temporarily adjusted ahead of scheduled inspections. The shift comes as the regulator continues to raise concerns about data integrity, manufacturing hygiene, documentation practices and quality controls at some Indian pharmaceutical facilities.
Key takeaways
- The share of unannounced FDA inspections in India increased from 47% in FY2025 to 87% in FY2026.
- The FDA is seeking greater parity between inspections at domestic US facilities and overseas manufacturing sites.
- The agency says surprise inspections help it observe routine manufacturing practices rather than temporary inspection-day preparations.
- FDA officials have raised concerns about destroyed manufacturing records, data-integrity failures and poor sanitation at some Indian facilities.
- The US is a critical export market for Indian pharmaceutical companies, particularly generic-drug manufacturers.
- Recent regulatory outcomes have been mixed: some Indian facilities have received warning letters or Form 483 observations, while others have completed inspections with more favourable classifications.
- Drugmakers will need stronger everyday compliance systems, documentation, supplier oversight and quality-control processes.
FDA increases unannounced inspections in India
The FDA’s move towards surprise inspections is becoming a central part of its oversight of foreign pharmaceutical manufacturers.
According to figures shared by Elizabeth Miller, associate commissioner for inspections and investigations at the FDA’s Office of Inspections and Investigations, the proportion of unannounced inspections in India rose from 47% in FY2025 to 87% in FY2026.
The corresponding proportion in China increased from 19% to 61% during the same period.
The figures were disclosed at the Association for Accessible Medicines’ GRx+Biosims conference in November 2026. Miller said the agency had substantially increased the use of unannounced overseas inspections to bring its oversight of foreign facilities closer to the approach used for domestic manufacturers.
The change is important because pharmaceutical manufacturing is increasingly global. A medicine sold in the United States may be manufactured, tested, packaged or supplied through facilities located in several countries.
The FDA therefore needs to assess whether overseas facilities meet the same quality standards expected of manufacturers operating within the US.
The regulator’s objective is not simply to increase the number of inspections. It wants to observe how factories operate under ordinary conditions, including how employees document production, handle deviations, maintain equipment and respond to quality problems.
Why the FDA wants surprise inspections
Traditionally, foreign manufacturing facilities could receive advance notice of an FDA inspection. Advance notice helped companies arrange access, prepare documentation and ensure that relevant employees were available.
However, regulators and US lawmakers have raised concerns that advance notice could allow manufacturers to temporarily improve conditions before inspectors arrive.
For example, a facility could prioritise cleaning, organise records, address visible maintenance problems or prepare employees for inspection questions.
These activities may make it more difficult for inspectors to understand the conditions under which the facility normally operates.
An unannounced inspection changes that dynamic.
Inspectors can observe production activities, laboratory practices, documentation systems and facility conditions without the same level of preparation by the manufacturer.
FDA officials say this approach provides a more realistic picture of manufacturing operations and helps identify problems that might not be visible during a scheduled inspection.
The agency announced plans in May 2025 to expand unannounced inspections of foreign manufacturing facilities producing medical products and food. The latest figures suggest that the policy is now being implemented more extensively in major pharmaceutical manufacturing countries, including India and China.
Data-integrity failures remain a major concern
The increase in surprise inspections comes alongside continuing FDA concerns about data integrity at Indian pharmaceutical facilities.
Data integrity refers to the accuracy, completeness, consistency and reliability of information generated during pharmaceutical manufacturing and testing.
Drugmakers must maintain records showing that their products were manufactured according to approved procedures and tested against required quality standards.
These records include laboratory results, equipment logs, production documents, batch records, deviations, stability studies and quality-control reports.
If records are incomplete, altered, destroyed or unreliable, regulators may not be able to establish whether a medicine meets the required quality standards.
In November 2026, Constance Richard-Math, the FDA’s deputy country director in India, said the agency continued to identify serious data-integrity problems at Indian pharmaceutical manufacturing facilities and clinical research organisations.
She described cases in which important documents relating to analytical testing, manufacturing procedures and storage had been discarded, including records destroyed using paper shredders.
The concerns are significant because pharmaceutical regulators rely heavily on documented evidence. A manufacturer cannot establish that a product is safe and meets specifications simply by claiming that its production process was properly controlled.
The underlying records must support that claim.
The FDA official also warned that manufacturers need to examine their suppliers, vendors and other external partners rather than focusing only on their own facilities.
A company can maintain strong internal quality systems but still face risks if a supplier, contract manufacturer or testing laboratory operates with inadequate controls.
Poor sanitation and manufacturing conditions under scrutiny
Data integrity is not the only issue attracting regulatory attention.
The FDA has also identified poor sanitation and unacceptable manufacturing conditions at some facilities.
Pharmaceutical manufacturing requires controlled environments because contamination can affect the safety, quality and effectiveness of medicines.
Factories must maintain appropriate cleaning procedures, equipment conditions, water systems, air-handling systems and controls to prevent contamination.
These requirements become particularly important for sterile medicines, injectable products and other formulations where contamination can create serious patient-safety risks.
The FDA has reported instances of facilities with visibly poor conditions, including dirty and deteriorated manufacturing environments.
The agency has urged companies to identify problems before they lead to product failures, recalls or supply disruptions.
For Indian manufacturers, this means compliance cannot be limited to preparing for inspections. Facilities must maintain consistent standards across shifts, production batches, laboratories and supplier networks.
What happens during an FDA inspection?
FDA inspections assess whether a manufacturing facility follows Current Good Manufacturing Practice requirements, commonly known as cGMP.
These regulations establish minimum standards for manufacturing, processing, packaging and holding pharmaceutical products.
An inspection can cover several areas:
| Inspection area | What the FDA examines |
|---|---|
| Manufacturing processes | Whether production follows approved procedures |
| Laboratory testing | Whether medicines meet established specifications |
| Data integrity | Whether records are accurate, complete and reliable |
| Documentation | Whether manufacturing and testing activities are properly recorded |
| Equipment and facilities | Whether machinery and premises are maintained appropriately |
| Contamination controls | Whether cleaning and prevention systems are effective |
| Quality management | Whether deviations, complaints and failures are investigated |
| Supplier oversight | Whether vendors and contractors meet quality requirements |
Inspectors may review records, examine production areas, interview employees, inspect laboratory systems and evaluate how the company handles manufacturing deviations.
The focus is not just whether a facility has written procedures. The FDA also checks whether employees follow those procedures in actual operations.
This distinction is especially important under unannounced inspections because the regulator can observe routine activities without relying entirely on preparations made for a scheduled visit.
FDA inspection outcomes: Form 483, OAI, VAI and NAI explained
An FDA inspection does not automatically result in a warning letter or a manufacturing shutdown.
The regulator uses different classifications and enforcement mechanisms depending on the findings and the company’s response.
| FDA term | Meaning | Possible implication |
|---|---|---|
| Form FDA 483 | Observations issued when inspectors identify conditions that may violate regulations | Company is expected to respond and address the observations |
| OAI | Official Action Indicated | Serious regulatory concerns that may warrant enforcement action |
| VAI | Voluntary Action Indicated | Issues identified, but the FDA does not currently recommend official regulatory action |
| NAI | No Action Indicated | No objectionable conditions or practices were found that warrant action |
A Form 483 is not itself a final regulatory decision or a warning letter. It records inspectors’ observations at the conclusion of an inspection.
The company generally has an opportunity to respond with explanations and corrective and preventive actions.
An OAI classification is more serious and can affect regulatory approvals and commercial operations. Depending on the circumstances, it may lead to further regulatory action.
VAI and NAI outcomes are generally less severe, although companies must continue to maintain compliance.
Understanding these distinctions is important when assessing reports about Indian pharmaceutical inspections. An inspection with several Form 483 observations does not automatically mean that the facility has been prohibited from manufacturing or exporting medicines.
Recent examples show a mixed compliance picture
The FDA’s increased inspection activity is taking place alongside a range of outcomes at Indian pharmaceutical facilities.
Reliance Life Sciences receives FDA warning letter
In August 2026, the FDA issued a warning letter to Reliance Life Sciences Private Limited following an inspection of its facility in Navi Mumbai.
The inspection took place from February 19 to February 27, 2026.
The FDA identified significant Current Good Manufacturing Practice violations, including failures to ensure that laboratory records contained complete data from the tests required to establish compliance with specifications.
A warning letter is a formal communication identifying significant regulatory violations and requiring the company to take corrective action.
The letter warned that inadequate manufacturing methods, facilities or controls could mean the affected products were considered adulterated under US law.
The case illustrates why data integrity remains a major regulatory priority.
Granules India receives 11 observations
Granules India’s Gagillapur facility in Hyderabad completed an FDA inspection between October 19 and October 30, 2026, with 11 observations recorded on Form FDA 483.
The company said none of the observations related to data integrity or cross-contamination.
The observations concerned areas including investigations, change control, process and equipment qualification, visual-inspection controls and documentation practices.
Granules said it would submit a comprehensive response to the FDA within the stipulated period and stated that there was no impact on manufacturing or distribution from the facility.
The inspection was significant because it was the first FDA inspection at the facility since a warning letter issued in February 2025.
Dr Reddy’s Hyderabad facility receives VAI classification
Dr Reddy’s Laboratories announced in November 2026 that the FDA had closed its inspection of the company’s formulations manufacturing facility, FTO-3, in Bachupally, Hyderabad, with a Voluntary Action Indicated classification.
The company had earlier disclosed that the inspection took place in August 2026.
A VAI classification indicates that the agency identified issues that did not warrant recommended official action at that stage.
The outcome demonstrates that increased regulatory scrutiny does not necessarily result in the most severe enforcement measures.
The cases underline the importance of evaluating each facility’s actual inspection findings rather than treating all FDA inspections as equivalent.
Why the US market matters so much to Indian drugmakers
The United States is one of the most important markets for India’s pharmaceutical industry.
Indian companies supply generic medicines, active pharmaceutical ingredients, complex formulations and other pharmaceutical products to US buyers.
The market is particularly important for generic-drug manufacturers because the US has a large healthcare system and significant demand for affordable medicines.
Industry estimates cited in Indian pharmaceutical reporting put the US share at roughly one-third to 40% of India’s pharmaceutical exports or relevant company revenues, depending on the measure and company group being considered.
This commercial exposure makes FDA compliance a strategic business issue.
A serious regulatory problem at a manufacturing facility can affect product approvals, shipments, customer confidence and future business opportunities.
If a facility receives an OAI classification or faces an import restriction, the company may have to shift production to another approved site or address the identified violations before normal commercial activity can resume.
Such disruptions can increase costs and affect supply commitments.
For companies with multiple manufacturing facilities, the impact may be manageable if production can be transferred. For businesses dependent on a limited number of approved sites, the consequences can be more significant.
What surprise inspections mean for Indian pharmaceutical companies
The shift towards unannounced inspections changes how drugmakers need to manage compliance.
Previously, some facilities may have treated inspections as events requiring intensive preparation in the weeks before regulators arrived.
That approach is less useful when inspectors can visit without advance warning.
Companies now need to ensure that documentation, cleaning, equipment maintenance, laboratory practices and quality systems remain inspection-ready every day.
This could increase compliance expenditure across the industry.
Drugmakers may need to invest in:
- Electronic documentation and stronger data controls.
- Employee training and quality-management systems.
- Continuous monitoring of manufacturing conditions.
- Internal audits that identify problems before regulators do.
- Better supplier and contract-manufacturer oversight.
- More effective investigations into deviations and product failures.
- Stronger systems for equipment qualification and process validation.
These investments can increase short-term operating costs, but they can also reduce the risk of costly regulatory disruptions.
For larger companies, the spending may be easier to absorb. Smaller manufacturers and contract research or manufacturing organisations could face greater pressure to upgrade their systems.
Will stricter FDA inspections affect India’s pharmaceutical exports?
The increase in surprise inspections does not automatically mean Indian pharmaceutical exports will decline.
The FDA’s stated objective is to ensure that medicines supplied to US patients meet consistent quality requirements, regardless of where they are manufactured.
India remains an important supplier of affordable generic medicines to the United States.
Stronger inspection standards could help credible manufacturers demonstrate that their products meet international quality expectations.
However, facilities that fail to maintain compliance could face additional scrutiny, warning letters, import restrictions or delays in approvals.
The distinction between well-managed manufacturers and companies with persistent quality problems may become more visible.
In the longer term, companies with strong quality systems could benefit from improved customer confidence, while manufacturers that depend on short-term corrective measures may face greater regulatory and commercial risks.
The bigger picture
The FDA’s increase in unannounced inspections reflects a broader change in how global pharmaceutical supply chains are regulated.
Medicines are manufactured across multiple countries, but patients expect consistent safety and quality standards. Regulators therefore need to assess foreign facilities with the same seriousness applied to domestic manufacturers.
For India, the stakes are particularly high because its pharmaceutical industry is deeply connected to the US generic-drug market.
The rise in surprise inspections from 47% to 87% in one year means manufacturers have less room to rely on inspection-specific preparations. Their daily operations, documentation and quality systems must consistently meet regulatory expectations.
The latest warnings about destroyed records, poor sanitation and supplier oversight also show that compliance extends beyond the factory floor. It includes laboratories, vendors, contractors and every part of the manufacturing chain that can influence medicine quality.
The policy could create additional costs for the industry, but it also places greater value on companies that can demonstrate reliable manufacturing practices.
Looking ahead
Indian drugmakers will need to prepare for a regulatory environment in which unannounced inspections become a routine feature of doing business with the US market. Companies are likely to increase investment in quality assurance, data-integrity systems, employee training, supplier audits and continuous monitoring of manufacturing operations. The FDA’s inspection findings and subsequent classifications will remain important indicators of how effectively individual facilities are adapting.
The key question is whether the industry can maintain consistent quality across its large and diverse manufacturing network while continuing to supply affordable medicines to international markets. For investors, the focus will be on inspection outcomes, warning letters, remediation costs, approval timelines and any disruption to US sales. For manufacturers, the message is that regulatory readiness must be built into everyday operations rather than reserved for the day an inspector arrives.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.



